<DOC>
	<DOCNO>NCT01491178</DOCNO>
	<brief_summary>To investigate safety efficacy long-term use Prazaxa® Capsules patient nonvalvular atrial fibrillation prevent occurrence ischemic stroke systemic embolism ( SEE ) .</brief_summary>
	<brief_title>Post-Marketing Surveillance Prazaxa® Long-term Use Patients With Nonvalvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Inclusion criterion : Patients nonvalvular atrial fibrillation never receive Prazaxa Capsules prevent occurrence ischemic stroke systemic embolism include . Exclusion criterion : None</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>